Articles related to DEPRESSION

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

Adjunctive cognitive behavioral therapy reduced depressive symptoms and ideation scores versus treatment as usual in a 93-patient feasibility trial of esketamine for major depression with suicidal ideation.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.

Consumer-facing guidance from Verywell Mind highlights how depression in adults over 60 frequently manifests as somatic complaints, cognitive changes, and social withdrawal rather than overt mood symptoms.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.